{
  "symbol": "OPT",
  "company_name": "Opthea Ltd ADR",
  "ir_website": "https://ir.opthea.com/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "Opthea’s Wet AMD Program to be Featured at FLORetina 2024",
          "url": "https://ir.opthea.com/news-releases/news-release-details/optheas-wet-amd-program-be-featured-floretina-2024-0",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main)\n\n# Release Details\n\n## \n\nOpthea’s Wet AMD Program to be Featured at FLORetina 2024\n\nNovember 26, 2024 at 7:00 AM EST\n\n[Download PDF](/node/11631/pdf)\n\nMELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.\n\nDetails are as follows:\n\nSession: | Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates  \n---|---  \nDate: | Friday, December 6, 2024, 11:25 AM CET  \nPresentation: | Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?  \nPresenter: | Professor Adnan Tufail, MBBS, MD, FRCOphth  \nProgram: | <https://floretina.com/floretinaicoormeeting2024/program>  \n  \n**About Opthea**\n\nOpthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).\n\nOpthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](https://www.globenewswire.com/Tracker?data=dp-HJHQUR2mH1uK_RmO4LMmSdVNCnUXXuvK-p_SMVVWFpRFJWrct8AZkUBeXuF3kPBzTQj4p8_JyRejAw1EyCktkn4_E6AlQPuFXbj_gnfU1cz4jALAdxnwqujrLWXM_WXeK61tEV0tiLWjvZdqVKA==), and ShORe, [NCT04757610](https://www.globenewswire.com/Tracker?data=dp-HJHQUR2mH1uK_RmO4LGQg0Zpla6u3TLr29ef1DPyMP59vyoOS6N_34yHPhK9Kqzzle8u63sAUMzjOet7hE5ga5j_FvDTpPC5EjBU3T8DXZ3U0vZJsumGp7WBjBCsA_657rhv5Bi4RpAer0goEHQ==)) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.\n\nTo learn more, visit our website at [www.opthea.com](https://www.globenewswire.com/Tracker?data=Und5rvHxlDsMHvuCK6Uhk-dP8U2590WjApVrGccT-_2NnXEUZvsfwfln4lRo6JZlxzy1B9yXh4y8RbyuHVktTQ==) and follow us on [X](https://www.globenewswire.com/Tracker?data=Z79DB2rSQz20s4rZFntdIuC384rJwK3GTTZJhsDGrOETSdIbJVvixJXtlqjWl0f2dEpiNFb0_ZYDVWqx1RJbKA==) and [LinkedIn](https://www.globenewswire.com/Tracker?data=F6cf6WtqZ45eCoZDND5dUmAusBh96DGOQd2tC4yk5N4rLrgFOzGD4MXYofw-d9G1Ywm1cE3WSap_A5S1TBhpapLDS-to_LNldDdoIwkyXOs=).\n\nAuthorized for release to ASX by Frederic Guerard, PharmD, CEO\n\n**Investor Inquiries** PJ Kelleher LifeSci Advisors, LLC Email: [pkelleher@lifesciadvisors.com](https://www.globenewswire.com/Tracker?data=kOAKLN736CNNbyj-cEI6-84DtxVCTukWDQ64Cy4SZg_n7_ZR9CI5Lw5jKnt4kyk0q7P9qCOAqqdKmlZY2c9FDCMPlc4nH_6Q96ccBczLAkjSUh1Dl_aK21WoBa-QySkW) Phone: 617-430-7579 \n\n**Media Inquiries** Silvana Guerci-LenaNorthStream Global PartnersEmail: [silvana@nsgpllc.com](https://www.globenewswire.com/Tracker?data=dkFTTAomwW_eddsP7kYXHBVEF3vgjxhxtwYFKuXhpPLVAbZFk5pVLMLt2xhF0EajQD115zF1hqGq-DuLOuUiu_RXszVGlfKZUAZ60G1xpmE=)\n\nJoin our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email: [info@opthea.com](https://www.globenewswire.com/Tracker?data=h-tEJIKHToqs31OiH207SnpTrb_wjKq78ovnzB0X55x-rbrg-fcdy8SRElQOTQPjiF_vkBgPeWf83mDKmkEEGw==) Web: [www.opthea.com](https://www.globenewswire.com/Tracker?data=Und5rvHxlDsMHvuCK6UhkzD32BkrE5dQ1Mh92ufLPZ0S6vFgpwNGxQbL7tIpAY8t6970yvGWRPZPer7XXmkDFg==)\n\nSource: Opthea Limited\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI4OTg2NiM2NjEwNTkxIzUwMDEyMTgwNg==)![](https://ml.globenewswire.com/media/Y2YwNjVmNzYtZWU1OS00M2JkLTljNmYtMWUxNzY1MzdjNzE3LTUwMDEyMTgwNg==/tiny/Opthea-Limited.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/6b4960e3-b3f5-41cb-8993-66ea0b111361/small/unknown-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/6b4960e3-b3f5-41cb-8993-66ea0b111361)\n\nSource: Opthea Limited\n\npalette Branding\n\nApply your branding\n\n×\n\nLogo (.gif, .png)Logo Size\n\nNavigation Background Color\n\nTransparent\n\nNavigation Text ColorLightDark\n\nPrimary (dark color)Secondary (dark color)Tertiary\n\nSet BrandingRestore Default Branding\n"
        },
        {
          "title": "Opthea's Wet AMD Program to be Featured at FLORetina 2024",
          "url": "https://ir.opthea.com/static-files/c8d4ef4c-be36-4dff-b36f-e9c3f475d6ea",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Citi 2024 Global Healthcare Conference",
          "url": "https://ir.opthea.com/events/event-details/citi-2024-global-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main)\n\n# Event Details\n\n## Citi 2024 Global Healthcare Conference\n\nDec 5, 2024 1:45 PM EST\n\nPanel: Eyes Wide Open on OphthalmologyPresenter: Frederic Guerard, PharmD, CEO, Opthea\n\n[Webcast](https://kvgo.com/2024-global-healthcare-conference/opthea-limited-december)\n\n[Add to Outlook](/node/11606/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Opthea Limited, Inc - Citi 2024 Global Healthcare Conference&dates=20241205T184500Z/20241205T184500Z&details=Event Details: https://opthealimited.gcs-web.com/events/event-details/citi-2024-global-healthcare-conference%0A%0AWebcast: https://kvgo.com/2024-global-healthcare-conference/opthea-limited-december&location=&trp=false&sprop=&sprop=name:)\n\npalette Branding\n\nApply your branding\n\n×\n\nLogo (.gif, .png)Logo Size\n\nNavigation Background Color\n\nTransparent\n\nNavigation Text ColorLightDark\n\nPrimary (dark color)Secondary (dark color)Tertiary\n\nSet BrandingRestore Default Branding\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. See our Cookie Notice for details.[Cookie Notice](https://opthea.com/cookie-notice)\n\nCookies Settings Reject All Accept All Cookies\n"
        },
        {
          "title": "Jefferies London Healthcare Conference 2024",
          "url": "https://ir.opthea.com/events/event-details/jefferies-london-healthcare-conference-2024",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main)\n\n# Event Details\n\n## Jefferies London Healthcare Conference 2024\n\nNov 19, 2024 \n\nParticipant: Frederic Guerard, PharmD, CEO, Opthea \n\npalette Branding\n\nApply your branding\n\n×\n\nLogo (.gif, .png)Logo Size\n\nNavigation Background Color\n\nTransparent\n\nNavigation Text ColorLightDark\n\nPrimary (dark color)Secondary (dark color)Tertiary\n\nSet BrandingRestore Default Branding\n"
        },
        {
          "title": "Bell Potter Healthcare Conference",
          "url": "https://ir.opthea.com/events/event-details/bell-potter-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main)\n\n# Event Details\n\n## Bell Potter Healthcare Conference\n\nNov 18, 2024 3:00 PM AEDT\n\nPresenter: Frederic Guerard, PharmD, CEO, Opthea \n\npalette Branding\n\nApply your branding\n\n×\n\nLogo (.gif, .png)Logo Size\n\nNavigation Background Color\n\nTransparent\n\nNavigation Text ColorLightDark\n\nPrimary (dark color)Secondary (dark color)Tertiary\n\nSet BrandingRestore Default Branding\n"
        }
      ]
    },
    {
      "section_name": "Annual Reports",
      "links": [
        {
          "title": "Opthea Appendix 4E and Annual Report 2023.pdf",
          "url": "https://ir.opthea.com/static-files/7af67a75-42b2-4c71-a25c-9b7375bcc83f",
          "content": "\n"
        }
      ]
    }
  ]
}